UBS AM’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$87.6M Sell
6,262,277
-504,639
-7% -$7.06M 0.02% 564
2025
Q1
$92M Buy
6,766,916
+3,184,042
+89% +$43.3M 0.02% 564
2024
Q4
$73M Sell
3,582,874
-166,612
-4% -$3.4M 0.02% 584
2024
Q3
$109M Buy
3,749,486
+1,451,770
+63% +$42.3M 0.03% 495
2024
Q2
$53.4M Buy
2,297,716
+1,610,477
+234% +$37.4M 0.02% 604
2024
Q1
$14.1M Sell
687,239
-21,100
-3% -$433K 0.01% 898
2023
Q4
$15.2M Buy
708,339
+65,039
+10% +$1.4M 0.01% 850
2023
Q3
$13.3M Buy
643,300
+76,159
+13% +$1.57M 0.01% 860
2023
Q2
$13.1M Hold
567,141
0.01% 873
2023
Q1
$13.1M Buy
567,141
+23,218
+4% +$535K 0.01% 873
2022
Q4
$15.1M Buy
543,923
+13,719
+3% +$382K 0.01% 820
2022
Q3
$16.3M Buy
530,204
+42,799
+9% +$1.31M 0.01% 815
2022
Q2
$14.3M Buy
487,405
+52,578
+12% +$1.55M 0.01% 833
2022
Q1
$14M Sell
434,827
-5,209
-1% -$168K 0.01% 945
2021
Q4
$19.6M Buy
440,036
+5,302
+1% +$236K 0.01% 902
2021
Q3
$21.9M Buy
434,734
+4,863
+1% +$245K 0.01% 840
2021
Q2
$33.7M Buy
429,871
+131,587
+44% +$10.3M 0.01% 742
2021
Q1
$17M Sell
298,284
-111,399
-27% -$6.36M 0.01% 902
2020
Q4
$34.3M Sell
409,683
-85,224
-17% -$7.14M 0.02% 705
2020
Q3
$17.7M Buy
494,907
+2,238
+0.5% +$80.2K 0.01% 806
2020
Q2
$11.9M Buy
492,669
+426,528
+645% +$10.3M 0.01% 860
2020
Q1
$1.16M Buy
66,141
+8,286
+14% +$145K ﹤0.01% 1638
2019
Q4
$1.01M Sell
57,855
-2,017
-3% -$35.1K ﹤0.01% 1912
2019
Q3
$917K Buy
59,872
+10,461
+21% +$160K ﹤0.01% 1998
2019
Q2
$1.03M Buy
49,411
+19,666
+66% +$408K ﹤0.01% 1871
2019
Q1
$691K Buy
29,745
+9,972
+50% +$232K ﹤0.01% 1971
2018
Q4
$409K Buy
19,773
+5,073
+35% +$105K ﹤0.01% 2079
2018
Q3
$320K Buy
+14,700
New +$320K ﹤0.01% 2256